Johnson & Johnson’ s Executive Vice President and Chief Information Officer Jim Swanson says:“ In the next few years AI is going to play an even bigger role. The technology is currently being used to help our employees detect disease at earlier stages, accelerate drug discovery, assist with clinical trial recruitment, map a patient’ s anatomy before a procedure and help surgeons predict the best tool for surgery.”
AI and NLP integration for drug discovery Johnson & Johnson combines NLP with broader AI tools to advance drug discovery. By applying AI to de-identified medical datasets – including EHRs, lab results and genetic data— the company pinpoints biological variations that drive diseases.
NLP’ s strength here is in processing textual medical data. And, with this complemented by AI’ s molecular design
130 December 2025